What is the current stock price of CV Sciences, Inc. (CVSI)?

As of the latest market data, CV Sciences, Inc. (CVSI) is trading at $0.04. The stock has seen a gain of 15.94% today.

Does CV Sciences, Inc. (CVSI) pay a dividend?

Based on current data, CV Sciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of CV Sciences, Inc.?

The current market capitalization of CV Sciences, Inc. (CVSI) is approximately unavailable.

CVSI

CV Sciences, Inc.·Healthcare

0.04

15.942%(+0.01)

Market Closed

Last Updated: — ET

52W L: $0.0252W H: $0.10

CVSI NEWS

seekingalpha.com

Mar 26

CV Sciences, Inc. (CVSI) Q4 2025 Earnings Call Prepared Remarks Transcript

accessnewswire.com

Mar 26

CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results

SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for the third quarter 2025; Recognized gross margin of 49.0% for fiscal 2025, a significant improvement from 45.6% for 2024; Gross margin of 50.5% for the fourth quarter 2025 compared to 43.2% for the fourth quarter 2024 and 48.5% for the third quarter 2025; Cash balance of $0.3 million at year end compared to $0.5 million at the end of 2024; Reduced operating expenses by 17.2% to $7.7 million for fiscal 2025 compared to $9.4 million for 2024, excluding benefit from reversal of accrued payroll taxes; Recognized an adjusted EBITDA loss of $0.3 million for fiscal 2025 compared to $0.8 million for 2024; Recognized positive adjusted EBITDA of $0.1 million for the fourth quarter 2025, significantly improved from adjusted EBITDA losses of $0.4 million for the fourth quarter 2024 and $0.1 million for the third quarter 2025; Expanded +PlusCBD™ product offering with the launch of Ignite, a men's performance formula for vitality, recovery, libido and focus (Q3 2025); and Launched EMPOWR, a plant-based protein and creatine formula designed for total wellness (Q1 2026), and Completed successful debt restructuring designed to strengthen financial position and fuel future growth (Q1 2026).

accessnewswire.com

Mar 24

CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year end and fourth quarter ended December 31, 2025, after the stock market closes on Thursday, March 26, 2026. The Company will hold a conference call with the investment community at 1:30 p.m.

accessnewswire.com

Mar 10

CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth

SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per share. "We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant milestone in the Company's strategic plan to enhance financial flexibility and accelerate long-term growth," said Joseph Dowling, CEO of CV Sciences.

accessnewswire.com

Feb 26

CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness

With 20g of clean protein, 5g of creatine, and LactoSpore® probiotics, Empowr supports everyday strength, mental energy and digestive balance without dairy or added sugar. Simple, functional nutrition for modern living.

Company Profile

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

2013-02-12

Beta

0.51

Websitewww.cvsciences.com↗